Phase
Condition
Chest Pain
Cardiac Disease
Dysrhythmia
Treatment
Atrial Fibrillation Termination
Prespecified Ablation
Clinical Study ID
Ages 18-80 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
aged between 18 and 80 years old;
Patients undergoing a first-time ablation procedure for PersAF, and in spontaneousAF at the beginning of the procedure;
Diagnosed as persistent AF according to the latest clinical guidelines,with atrialfibrillation lasting for at least one month;
Ineffective or intolerable to ≥1 anti-arrhythmia drug treatment;
Patients must be able and willing to provide written informed consent to participatein this study;
Patients must be willing and able to comply with all study follow- up requirements.
Exclusion
Exclusion Criteria:
.Uncontrolled congestive heart failure, EF <35%;
. History of severe valve disease and/or prosthetic valve replacement;
. Myocardial infarction or stroke within 6 months;
. Severe congenital heart disease;
. Left atrial diameter ≥60mm;
. Contrast agent allergy;
. The use of anticoagulant drugs is contraindicated;
. Severe lung disease;
. Left atrial thrombus confirmed by preoperative esophageal ultrasound;
.Contraindications for cardiac catheterization;
.Prior left atrial ablation (surgical or catheter);
.Have performed any cardiac surgery within 2 months;
.Poor general health;
.Life expectancy < 12 months, including factors such as physical inability totolerate ablation or unstable disease conditions.-
Study Design
Connect with a study center
Shanghai Chest Hospital
Shanghai,
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.